- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02940392
Rezum FIM Optimization Study (Rezum FIM)
Rezum First in Man Feasibility Study for the Treatment of BPH With the Rezum System
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
La Romana, Dominican Republic
- Clinica Canela
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male subjects > 45 years of age who have symptomatic / obstructive symptoms secondary to BPH requiring invasive intervention.
- IPSS score of ≥ 15.
- Qmax: Peak flow rate ≤ 15 ml/sec.
- Post-void residual (PVR) < 300 ml.
- Prostate transverse diameter > 30 mm.
- Prostate volume between 20 to 120 gm.
- Voided volume ≥ 125 ml.
- Subject able to complete the study protocol in the opinion of the Principal Investigator.
- Subject must be willing to undergo the procedure without anesthesia.
Exclusion Criteria:
- History of any illness or surgery that in the opinion of the Principal Investigator may confound the results of the study.
- Presence of a penile implant.
- Any prior minimally invasive intervention (e.g. TUNA,Laser, Microwave) or surgical intervention for the symptoms of BPH.
- Currently enrolled in another clinical trial.
- Confirmed or suspected malignancy of prostate or bladder.
- Previous rectal surgery (other than hemorrhoidectomy) or history of rectal disease.
- Previous pelvic irradiation or radical pelvic surgery.
- Documented active urinary tract infection by culture or bacterial prostatitis within last year documented by culture (UTI is defined as >100,000 colonies per ml urine from midstream clean catch or catheterization specimen).
- Neurogenic bladder or sphincter abnormalities.
- Urethral strictures, bladder neck contracture or muscle spasms.
- Bleeding disorder (note that use of anti-platelet medication is not an exclusion criterion).
- Subjects who are interested in maintaining fertility.
Use of concomitant (or recent) medications to include the following:
- Beta blockers, antihistamines, anticonvulsants, and antispasmodics within 1 week of treatment, unless there is documented evidence of stable dosing for last 6 months (e.g., no dose changes).
- Alpha blockers, antidepressants, anticholinergics, androgens, or gonadotropin-releasing hormonal analogs within 2 weeks of treatment.
- 5-alpha reductase inhibitor within the last 6 months
- Subject is unable or unwilling to go through a "washout" period for the above medications prior to treatment.
- Subject has chronic urinary retention.
- Significant urge incontinence.
- Poor detrusor muscle function.
- Neurological disorders which might affect bladder or sphincter function.
- Bladder stones.
- Renal impairment.
- In the opinion of the Principal Investigator, subject will not be able to adequately tolerate a rigid cystoscopy-type procedure.
- Unable or unwilling to sign the Informed Consent Form (ICF) and/or comply with all the required follow-up requirements.
- Any cognitive disorder that interferes with or precludes a subject from directly and accurately communicating with the Principal Investigator regarding the study.
- Peripheral arterial disease with intermittent claudication or Leriches Syndrome (i.e., claudication of the buttocks or perineum).
- Biopsy of the prostate within 30 days prior to the Rezūm procedure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rezum Treatment
Patients will receive the Rezūm transurethral needle ablation procedure to treat benign prostatic hyperplasia.
|
The Rezūm System is designed to treat patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate "wet" thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death. The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in International Prostate Symptom Score
Time Frame: Baseline to 1 week, 1 month, 3 months, 6 months, 1 year, annually to 5 years
|
International Prostate Symptom Score (IPSS) scores were recorded at Baseline to 1 week, 1 month, 3 months, 6 months, 1 year, then annually to 5 years. The mean change in IPSS was calculated. The IPSS is a validated questionnaire used to screen for, rapidly diagnose, track the symptoms of, and suggest management of the symptoms of benign prostatic hyperplasia (BPH). Scoring ranges from 0 to 35 with overall scores of 0-7 correlated to mildly symptomatic, 8-19 correlated to moderately symptomatic and 20-35 correlated to severely symptomatic. A reduction in score from baseline corresponds to improved outcome post procedure. |
Baseline to 1 week, 1 month, 3 months, 6 months, 1 year, annually to 5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intra-procedural and Post-procedural Pain
Time Frame: Procedure Day, 1 day post procedure, 1 week post procedure, 1 month post procedure, 3 months post procedure ,6 months post procedure
|
Intra-procedural and post-procedural pain for each subject was assessed using the Wong Baker Pain Rating scale (0-10 with 0 indicating no pain and 10 indicating worst pain imaginable).
Each subject selected the response on the pain scale that he felt best represented his pain level.
Unless otherwise noted, the subjects were not given pain medications or anesthesia.
All subjects were given an anti-anxiety medication plus a Non-Steroidal Anti-Inflammatory Drug (NSAID) pre-procedure.
|
Procedure Day, 1 day post procedure, 1 week post procedure, 1 month post procedure, 3 months post procedure ,6 months post procedure
|
Number of Subjects Requiring Catheterization Post Procedure
Time Frame: 1 day post procedure, 1 week post procedure, 1 month post procedure
|
All subjects were kept at the clinic for observation for 24 hours post-procedure.
The number of subjects requiring post-procedure catheterization were recorded.
|
1 day post procedure, 1 week post procedure, 1 month post procedure
|
Post Procedure Catheterization Duration
Time Frame: 1 month post procedure
|
Measures the duration (days) of catheterization for subjects who required catheterization post procedure.
Post-procedure catheterization was allowed if the Principal Investigator determined that the subject had symptoms of retention (defined as failure to void within 8 hours post procedure) or required catheterization for other safety reasons.
|
1 month post procedure
|
Lesion Characteristics Via MRI (Changes in Lesion Volume)
Time Frame: 1 week , 1 month, 3 months, 6 months post procedure
|
Lesion size and treated tissue resorption rate was measured by gadolinium enhanced MRI on all subjects at 1 week, 1 month, 3 months, and 6 months post-procedure.
The percent change in lesion volume was calculated.
|
1 week , 1 month, 3 months, 6 months post procedure
|
Lesion Characteristics Via MRI (Changes in Prostate Volume)
Time Frame: 1 week, 1 month, 3 months, 6 months post-procedure
|
Lesion size and treated tissue resorption rate was measured by gadolinium enhanced MRI on all subjects at 1 week, 1 month, 3 months, and 6 months post-procedure.
The percent change in prostate volume was calculated.
|
1 week, 1 month, 3 months, 6 months post-procedure
|
Lesion Characteristics Via MRI (Changes in Transition Zone Volume)
Time Frame: 1 week, 1 month, 3 months, 6 months post-procedure
|
Lesion size and treated tissue resorption rate was measured by gadolinium enhanced MRI on all subjects at 1 week, 1 month, 3 months, and 6 months post-procedure.
The percent change in transition (TZ) zone volume was calculated
|
1 week, 1 month, 3 months, 6 months post-procedure
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1633-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Benign Prostatic Hyperplasia
-
St. Joseph's Healthcare HamiltonOntario Ministry of Health and Long Term CareCompletedBenign Prostatic HyperplasiaCanada
-
San Carlo di Nancy HospitalElesta S.R.L.CompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy | Benign Prostatic Hypertrophy With Outflow Obstruction | Prostate HyperplasiaItaly
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
Catholic University of the Sacred HeartCompletedBenign Prostatic Hyperplasia (BPH) | Benign Prostatic Enlargement (BPE)Italy
-
Boston Scientific CorporationCompletedProstatic Hyperplasia | Benign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy | Prostatic Hypertrophy, Benign | Adenoma, Prostatic | Prostatic Adenoma | RezumDominican Republic, Czechia, Sweden
-
IMBiotechnologies Ltd.CompletedBenign Prostatic Hyperplasia | Benign Prostatic HypertrophyCanada
-
IRCCS Policlinico S. MatteoCompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy With Outflow ObstructionItaly
-
American Medical SystemsCompletedBenign Prostatic Hyperplasia | BPH | Benign Prostatic Hypertrophy | Prostate Disease
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Not yet recruitingLower Urinary Tract Symptoms | Benign Prostate Hyperplasia | Benign Prostatic Hypertrophy With Outflow Obstruction
-
Assiut UniversityNot yet recruiting
Clinical Trials on Rezum System
-
Boston Scientific CorporationCompletedProstatic Hyperplasia | Benign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy | Prostatic Hypertrophy, Benign | Adenoma, Prostatic | Prostatic Adenoma | RezumDominican Republic, Czechia, Sweden
-
Chinese University of Hong KongTerminatedBenign Prostatic HyperplasiaHong Kong
-
Can-Am HIFU Inc.Recruiting
-
Boston Scientific CorporationCompletedBenign Prostatic Hyperplasia | Lower Urinary Tract SymptomUnited States
-
NeoTract, Inc.RecruitingBenign Prostatic HyperplasiaUnited States, United Kingdom
-
Assiut UniversityNot yet recruiting
-
Hisar Intercontinental HospitalCompletedProstatic HyperplasiaTurkey
-
University of ManitobaNot yet recruitingBenign Prostatic HyperplasiaCanada
-
Seoul National University HospitalRecruitingProstatic Hyperplasia of the Medial LobeKorea, Republic of
-
Weill Medical College of Cornell UniversityBoston Scientific CorporationSuspendedBenign Prostatic HyperplasiaUnited States